Afatinib CAS 439081-18-2 Puritas >99.5% (HPLC)

Description:

Nomen chemicum: Afatinib

Synonyma: BIBW2992

CAS: 439081-18-2

Puritas: >99.5% (HPLC)

Aspectus: Off-Pulvis alba

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple intermedia de Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
acetaldehyda Diethyl acetalis CAS 3616-56-6
trans-4-dimethylaminocrotonic Acidum hydrochloridum CAS 848133-35-75
Diethylphosphonoaceticum acidum CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl) -7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5

Chemical Properties:

Nomen chemicum	Afatinib
Synonyma	BIBW2992;BIBW-2992;BIBW2992 Free Base;Tomtovok;(S, E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(Dimethylamino)but-2-Enamide
CAS Number	439081-18-2
CATTUS Number	RF-PI2033
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C24H25ClFN5O3
M. Pondus	485.94
Solubilitas	Solutum in DMSO
Density	1.380
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Off-Pulvis alba
Lepidium sativum	HPL, NMR
Puritas / Analysis Methodus	>99.5% (HPLC)
Liquescens punctum	1000~102.0℃
Damnum in Siccatio	<0.50%
Residere in Ignition	<0.20%
Totalis immunditias	<0.50%
Metalla gravis	≤20ppm
NMR Imaginum	Conformat ut Structure
Test Standard	Enterprise Standard
Fasciae vita	XXIV menses si proprie Repono
Consuetudinem	API;Afatinib;Afatinib Dimaleate;NSCLC

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Afatinib, etiam ut BIW-2992, (CAS: 439081-18-2) est secunda generatio potens et immedicabilis dualis inhibitor incrementi epidermalis factoris receptoris (EGFR) et incrementi epidermalis humani factoris receptoris 2 (ER2) tyrosini kinasi; evoluta Boehringer Ingelheim, Germania.Capax est irreversibiliter inhibere activitates tyrosinae kinasi Michaelem reactionem cum thiol coetus cysteini in positione 797 EGFR subeundo.Die 12 mensis Iulii anno 2013 novum medicamentum pro anti-parva cellula pulmonis cancri ab US FDA probatum sub artis Gilotrif nomine factum est.Hoc medicamentum tabula est.Ponitur pro curatione aegrorum praecogniti cum cancro metastatico non-parvo cellae pulmonis (NSCLC) cum amissione 19th exon vel L858R mutationem in 21 exon tumoris epidermalis factoris receptoris (EGFR) confirmati utens ornamentum approbatum. apud FDA.Medicamentum etiam efficax est in curatione aegrorum HER2-positivorum cum carcinomate carcinomatis provectis.Afatinib ad genus medicamentorum quae inhibitores tyrosini kinase vocantur.Inhibitores tyrosini kinasi designantur ad impediendam actionem enzyme specificae kinasi vocati tyrosini.Hoc enzyme magnum munus in cellularum munere agit, et agit in incremento et progressu promovendo.Afatinib operatur munus duorum generum kinasium tyrosinorum inhibere: factor incrementi epidermalis receptoris (EGFR) et Her2, quae pluribus generibus cancri "expressae" sunt.Munus harum tyrosinae kinases impediendo, Afatinib impediat cellulas cancer a dividendo et crescendo.